Genetically Validated Drug Targets in Leishmania: Current Knowledge and Future Prospects.

Area of Science:

• Parasitology
• Molecular Biology
• Drug Discovery

Background:

• Limited high-throughput screening campaigns for Leishmania drug targets exist.
• A small number of validated essential genes hinder parasite drug development.
• Genetic and chemical methods have identified few essential Leishmania genes.

Purpose of the Study:

• To discuss the current status of genetic target validation in Leishmania research.
• To review gene deletion attempts in Leishmania and Trypanosoma cruzi.
• To assess methods for identifying potential drug targets and explain the lack of large-scale approaches in Leishmania.

Main Methods:

• Review of published gene deletion attempts in Leishmania (200 genes) and Trypanosoma cruzi (36 genes) since 1990.
• Definition of a quality score for genetic deletion techniques.
• Analysis of genome-scale gene disruption techniques in other parasitic protozoa.

Main Results:

• Gene deletion attempts have been made for 200 Leishmania and 36 Trypanosoma cruzi genes.
• A quality score system for genetic deletion techniques was proposed.
• Comparison of Leishmania's approach to other parasitic protozoa revealed a lack of similar large-scale efforts.

Conclusions:

• Genetic target validation in Leishmania requires improved and scalable methods.
• CRISPR/Cas9 gene editing offers promising prospects for advancing Leishmania drug discovery.
• Future efforts should focus on robust gene disruption techniques to identify essential targets for anti-Leishmania drug development.